Conexiant’s news site is now MDSpire News. Learn more
Advertisement
ESMO26: Toni Choueiri, MD, on KEYNOTE-564
Final analysis of the pivotal KEYNOTE-564 trial in kidney cancer presented by Toni Choueiri, MD. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma.
The article examines the objective, findings, and clinical context described in ESMO26: Toni Choueiri, MD, on KEYNOTE-564.
Approach:
Follow-up: The final analysis was presented after 7 years of follow-up.
Treatment: The trial evaluated adjuvant pembrolizumab.
Key Findings:
After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival in high-risk clear-cell renal cell carcinoma.
After 7 years of follow-up, adjuvant pembrolizumab continued to extend overall survival in high-risk clear-cell renal cell carcinoma.
Interpretation:
The final analysis of KEYNOTE-564 found that adjuvant pembrolizumab continued to extend disease-free and overall survival in high-risk clear-cell renal cell carcinoma.
Limitations:
The provided context does not include numerical results, study methods, or details about adverse events.